A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial [0.03%]
VIABLE试验第一阶段的成果：一种用于整块切除膀胱肿瘤的经尿道机器人平台的新方法
Jeremy Yuen-Chun Teoh,Francesco Maria Bracco,Julius Ho-Fai Wong et al.
Jeremy Yuen-Chun Teoh et al.
The Virtuoso Endoscopy System (VES) is a novel robotic surgical system designed for transurethral excision of bladder lesions. In this first-in-human study, we evaluated the feasibility of using the VES to perform safe and effective excisio...
Circulating Tumor DNA in Muscle-invasive Bladder Cancer: Promise, Pitfalls, and Path Forward [0.03%]
肌层浸润性膀胱癌的循环肿瘤DNA：希望、挑战及未来方向
Clara Cerrato,Morgan Rouprêt,Maria Carmen Mir
Clara Cerrato
Recent results from IMvigor 011 constitute the first prospective, randomized validation of a therapeutic strategy guided by circulating tumor DNA (ctDNA) status in urothelial cancer. We discuss the promise of ctDNA for guiding treatment dec...
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study [0.03%]
PROpel研究中，与安慰剂联合阿比特龙相比，接受奥拉帕利联合阿比特龙治疗的转移性去势抵抗性前列腺癌患者的患者报告结局
Andrew J Armstrong,Fred Saad,Mototsugu Oya et al.
Andrew J Armstrong et al.
Background and objective: The phase 3 PROpel study showed a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) with olaparib + abiraterone versus placebo + abi...
Prognostic Role of Different T1 Substaging Systems on Recurrence and Progression in Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis [0.03%]
不同T1期分期系统对非肌层浸润性膀胱癌复发和进展的预后价值：系统评价和meta分析
Andrea Piccolini,Stefano Moretto,Vittorio Fasulo et al.
Andrea Piccolini et al.
Background and objective: Different substaging methods have been proposed for risk stratification of T1 non-muscle-invasive bladder cancer; however, no consensus exists. This systematic review and meta-analysis evaluates ...
A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma [0.03%]
上尿路尿路上皮癌腔内治疗的系统评价
Chris Ho-Ming Wong,David Ka-Wai Leung,Ivan Ching-Ho Ko et al.
Chris Ho-Ming Wong et al.
Background and objective: Radical nephroureterectomy is the standard of care for management of upper tract urothelial carcinoma (UTUC), but treatment-associated morbidity is not uncommon. Intracavitary therapy has emerged...
Gender-based Differences in Psychosocial Well-being Among Bladder Cancer Survivors [0.03%]
膀胱癌幸存者中基于性别的心理社会健康差异
Aidan S Weitzner,Aurora J Grutman,Alyssa Arbuiso et al.
Aidan S Weitzner et al.
Background and objective: While gender disparities in bladder cancer are well documented in sexual and functional health domains, mental and social well-being among survivors are not elucidated fully. We aimed to investig...
Value of Additional Systematic Cores During Magnetic Resonance Imaging-guided Targeted Biopsy in Prostate Cancer Screening for Young Men: Results from the PROBASE Trial [0.03%]
前列腺癌筛查年轻男性系统性核心穿刺活检的额外价值：PROBASE试验结果
Rouvier Al-Monajjed,Matthias Boschheidgen,Jale Lakes et al.
Rouvier Al-Monajjed et al.
Background and objective: While magnetic resonance imaging (MRI)-guided targeted biopsy (TBx) is becoming an integral part of early detection of prostate cancer (PC), its role in screening of younger men remains unclear. ...
PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications [0.03%]
转移性去势抵抗性前列腺癌中聚腺苷二磷酸核糖聚合酶抑制剂的机制、理据及临床应用
Stéphane Oudard,Marc-Olivier Timsit,Denis Maillet et al.
Stéphane Oudard et al.
Background and introduction: Over the past 15 yr, significant progress has been made in the management of prostate cancer (PC), including the development of chemotherapy, androgen receptor pathway inhibitors (ARPIs), and,...
Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial [0.03%]
不 favorable-risk前列腺癌患者新辅助抗雄治疗联合或不联合MEK或SRC抑制剂II期随机临床试验
Raag Agrawal,Adam B Weiner,Julie Livingstone et al.
Raag Agrawal et al.
Background and objective: It is thought that androgen deprivation therapy (ADT) resistance and subsequent prostate cancer progression via epithelial-mesenchymal transition (EMT) is induced by the SRC and MEK pathways. We ...
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial [0.03%]
放射治疗联合长效促黄体生成素释放激素拮抗剂与激动剂作为非常高危局限期或局部晚期前列腺癌患者辅助治疗的III期随机对照试验(EORTC GUCG-1414)
Thomas Zilli,Dirk Böhmer,Andreas Roeder et al.
Thomas Zilli et al.
Background and objective: External beam radiotherapy (EBRT) combined with long-term androgen deprivation therapy (ADT) is standard for high-risk prostate cancer. EORTC 1414 compared ADT with a luteinizing hormone-releasin...